|
Post by peppy on Mar 23, 2018 19:16:57 GMT -5
North Shore University Hospital would be a nice "Afrezza Center of Excellence". I think its the teaching hospital for NYU. How crazy would it be that the big break afrezza gets is because of heart surgery by one of its users. Every university hospital is a good place for Afrezza. That university endo's are not prescribing Afrezza is backwards. It makes me think of Universities differently. As in, "Old McDonald had a farm, ey I ey I O."
|
|
|
Post by mnkdfann on Mar 23, 2018 21:54:06 GMT -5
Al had the guts and smarts to avoid selling cheap and take the long road. However, taking the long road required settling for a sub-optimal Sanofi deal. That seems a little contradictory, but perhaps that is just me.
|
|
|
Post by akemp3000 on Mar 23, 2018 22:01:34 GMT -5
This is being made way to complicated. Use Afrezza and your time-in-range can be comparable to that of a non-diabetic with a healthy pancreas plus you won't have to worry about complications from hypos. Use any other prandial alternative and you CANNOT achieve these results. It's now up to Mike and Dr. Kendall to use existing data or create new data to communicate this message within FDA guidelines.
|
|
|
Post by agedhippie on Mar 24, 2018 10:25:21 GMT -5
This is being made way to complicated. Use Afrezza and your time-in-range can be comparable to that of a non-diabetic with a healthy pancreas plus you won't have to worry about complications from hypos. Use any other prandial alternative and you CANNOT achieve these results. It's now up to Mike and Dr. Kendall to use existing data or create new data to communicate this message within FDA guidelines. Your problem is that, from personal experience, doctors are already convinced that you can get non-diabetic numbers if you follow the rules with the existing treatments. Their view is that it is the diabetics screwing up - btw this is a sore point with diabetics.
|
|
|
Post by lennymnkd on Mar 24, 2018 12:04:02 GMT -5
Agedhippe ; it’s a lot more convenient the afrezza way / and the whole story here is getting people to comply , when doctors are finally held accountable, compliance will mater / the day al had visions of is here CGM
|
|
|
Post by sayhey24 on Mar 24, 2018 12:32:56 GMT -5
North Shore University Hospital would be a nice "Afrezza Center of Excellence". I think its the teaching hospital for NYU. How crazy would it be that the big break afrezza gets is because of heart surgery by one of its users. NYU is the teaching hospital for NYU North Shore University Hospital is part of Northwell. Their Manhattan hospital is Lennox Hill which is a nice hospital whose ER is seldom as badly crowded as most. I had 2 kids at NSUH. What I can tell you is most of the students asking a zillion questions were from NYU. While affiliated with Northwell they also have some deal with NYU - en.wikipedia.org/wiki/North_Shore_University_HospitalRegardless it would be nice to see all these including LIJMC which is right down the road on the list of "Afrezza Centers of Excellence" patch.com/new-york/northport/best-hospitals-long-island-us-news-world-reportAged - we seem to have an unusual situation here concerning one of your other posts. Normally trial data is far superior to actual clinical results. In the case of afrezza the 171 and 175 results are not great but after 3 years afrezza is outperforming all expectations and its users are calling it life changing. For the "lazy" T2 what the 118 trial said is let them take more as they won't get the hypo. The current guidance says start with the 4u. It should say take the 8u. If they have no CGM and aren't checking BG they are always better to go bigger with the 8u and the 12u for bigger meals. If the 118 and the VDex findings and pretty much any T2 currently using afrezza has found, hypos for a T2 not taking other antiglycemics or basal are not an issue. Even with no follow-ups after the meal they will do far better than taking the metformin. The good news is Dr. Kendall is on the team and knows how the ADA works. In fact he helped write the rules. I suspect he is already putting together evidence from a meta-analysis that incorporated quality ratings in the analysis from the 65 lost studies. He can also use the pilot STAT to help justify the compelling nonexperimental clinical evidence. A case study by the NY Endo sure won't hurt either.
|
|
|
Post by akemp3000 on Mar 24, 2018 13:29:07 GMT -5
CGMs are going to expose the failure of current diabetes standards of care. Some will even spotlight the superiority of Afrezza. A ton of data is about to come in soon from many sources; CGM providers (Dexcom, Abbott's Libre), ancillary data providers (One Drop), diabetics, doctors and trial results. IMO, this will become a major topic of discussion at upcoming diabetes conferences and will be written about extensively. This new data should overwhelm and disrupt the current antiquated A1c thinking of doctors, the healthcare industry, insurance companies and many diabetics. If only this could happen overnight.
|
|
|
Post by careful2invest on Mar 24, 2018 14:06:19 GMT -5
Al had the guts and smarts to avoid selling cheap and take the long road. However, taking the long road required settling for a sub-optimal Sanofi deal. That seems a little contradictory, but perhaps that is just me. Yep, it's just you, Here again, a true mnkdfann would get this, but a short... well maybe not so much, and may attempt to find a blemish. This is my interpretation of what radgray68 is saying... Al avoided "selling cheap" because he did NOT SELL. Al settled for a "sub-optimal Sanofi deal" which was a partnership, not a sale. Although, it appeared that Al's options were very limited when he made the ill fated agreement with Sanofi. Which in hindsight, for reasons most of us are too well aware, nearly burried the company, but currently, there is still a company (Mannkind Corp) that solely still owns Afrezza, and is not a thing of the past. Hence the mention of Al Manns "guts and smarts" And imho, Mannkind is finally now on a well orchestrated path to success. Admittedly, a lot of work ahead, but on a positive path nonetheless. In addition, I am a true MNKD Fan! GLTA, Unless you are short MNKD!
|
|
|
Post by goyocafe on Mar 24, 2018 14:11:48 GMT -5
CGMs are going to expose the failure of current diabetes standards of care. Some will even spotlight the superiority of Afrezza. A ton of data is about to come in soon from many sources; CGM providers (Dexcom, Abbott's Libre), ancillary data providers (One Drop), diabetics, doctors and trial results. IMO, this will become a major topic of discussion at upcoming diabetes conferences and will be written about extensively. This new data should overwhelm and disrupt the current antiquated A1c thinking of doctors, the healthcare industry, insurance companies and many diabetics. If only this could happen overnight. This year would be nice!
|
|